Preview

User

Not a user? Register with this site Forgot your password?

Problems of Endocrinology

Advanced search

The role of body weight reduction and treatment with metformin in the recovery of the menstrual function in women presenting with polycystic ovary syndrome and excessive body weight

https://doi.org/10.14341/probl201157214-18

Abstract

A total of 40 women presenting with polycystic ovary syndrome (PCOS) and excessive body weight/obesity were randomly allocated to 3 groups. The patients in group 1 were advised to change the life style (including consumption of a low-calory diet and regular physical exercises), those making up group 2 had to change the life style and take metformin (850 mg twice daily), the patients of group 3 used metformin without modifying their life style. Thirty three patients completed the study. Those in groups 1 (n=14) and 2 (n=10) experienced a similar significant reduction of both the body weight and the HOMA index. In group 3 (n=9), these characteristics remained virtually unaltered. The fraction of women displaying the positive menstrual response during the treatment was not significantly different in groups 1 and 2 (50 and 60% respectively; p=0.77) whereas none of the patients in group 3 showed the positive menstrual response (the difference between this and the two previous groups was significant; p=0.035). A significant decrease in the testosterone level was documented in the women of group 2. The authors conclude that it was the reduction of the body weight rather than regular intake of metformin at a daily dose of 1700 mg that contributed to the improvement of the menstrual function in women with PCOS and the excessive body weight.

References

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrin Reviews 1997;18:6:774-800.

2. Nestler J.E., Jakubowicz D.J. et al. In the polycystic ovary syndrome insulin stimulate human thecal testosterone production via its own receptor by using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;80:2001-2005.

3. Nestler J.E., Powers L P. et al. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83-89.

4. Kocak M., Caliskan E., Simsir C. et al. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002;77:1:101-106.

5. Lord J.M., Flight I.H., Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327;951-956.

6. Nestler J.E., Jakubowicz D.J., Evans W.S. et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-1880.

7. Pasquali R., Gambineri A., Biscotti D. et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-2774.

8. Tang T., Glanville J., Hayden C.J. et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006;21:1:80-88.

9. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:1:41-47.

10. Morley J.E., Patrick P., Perry H.M.III Evaluation of assays available to measure free testosterone. Metabolism 2002;5:554-559.

11. Matthews D., Hosker J., Rudenski A. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:12-19.

12. Crosignani P.G., Colombo M., Vegetti W. et al. Overweight and obese anovulatory patients with polycystic ovaries: Parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003;18:9:1928-1932.

13. Foreyt J.P., Poston W.S. Obesity: a never-ending cycle? Int J Fertil Women's Med 1998;43:111-116.

14. Hollmann M., Runnebaum B., Gerhard I. Effect of weight loss on the hormonal profile in obese, infertile women. Hum Reprod 1996;11:9:1884-1891.

15. Attia G.R., Rainey W.E., Carr B.R. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001;76:3:517-524.

16. Mansfield R., Galea R., Brincat M. et al. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 2003;79:956-962.


Review

For citations:

Popova P.V., Riazantseva E.M., Zazerskaia I.E., Ivanova L.I., Grineva E.N. The role of body weight reduction and treatment with metformin in the recovery of the menstrual function in women presenting with polycystic ovary syndrome and excessive body weight. Problems of Endocrinology. 2011;57(2):14-18. https://doi.org/10.14341/probl201157214-18

Views: 551


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)

11, Dm. Ul’yanova str., Moscow, Russian Federation, 117292

Processing of personal data
supported by NEICON (Elpub lab)